Newfound Research’s Abiomed Inc ABMD Stock Holding History

Newfound Research’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-217	Closed	-$69K	–	137
2021 Q1	$69K	Buy	217 +69	+47%	+$22.1K	0.16%	77
2020 Q4	$48K	Buy	+148	New	+$40.9K	0.12%	113

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Newfound Research's ABMD Position: Q2 2021 in Review

Newfound Research sold out of Abiomed Inc (ABMD) in Q2 2021, closing a stake of 217 shares — an estimated $69K sold.

Newfound Research first reported a position in ABMD in Q4 2020 and held it in 2 quarters. The position peaked at $69K in Q1 2021. 474 funds tracked by Wall St. Rank hold ABMD as of Q2 2021.

Newfound Research reported no remaining Abiomed Inc position as of Q2 2021 after selling out during the quarter.
Newfound Research sold 217 Abiomed Inc shares in Q2 2021, an estimated $69K.
Newfound Research first reported a position in Abiomed Inc in Q4 2020 and held it in 2 quarters.
Newfound Research's Abiomed Inc position peaked at $69K in Q1 2021.
474 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2021.

Based on Newfound Research's 13F filing for Q2 2021, filed 19 Jul 2021.